Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709157 | 0.89 | CA12 (0.45) | SMN1; SMN2LMNAPOLBCA1CA2 | |
| SCHEMBL27263918 | 0.87 | CA12 (0.43) | SMN1; SMN2LMNAPOLBCA1CA2 | |
| Water SCHEMBL27737003 | 0.86 | CA12 (0.42) | SMN1; SMN2LMNAPOLBCA1CA2 | |
| SCHEMBL465093 | 0.81 | CA12 (0.48) | SMN1; SMN2LMNACA12CA7CA14 | |
| Water SCHEMBL27714980 | 0.79 | CA12 (0.46) | SMN1; SMN2LMNACA12CA7CA14 | |
| SCHEMBL27896468 | 0.79 | CA12 (0.46) | SMN1; SMN2LMNACA12CA7CA14 | |
| SCHEMBL17443158 | 0.74 | CA1 (0.46) | SMN1; SMN2CA1CA2CA12CA7 | |
| SCHEMBL7297373 | 0.72 | ALDH1A1 (0.50) | SMN1; SMN2LMNAPOLBCA12CA7 | |
| SCHEMBL21210697 | 0.70 | LMNA (0.49) | SMN1; SMN2LMNAPOLBCA12CA7 | |
| SCHEMBL13968028 | 0.70 | CA12 (0.54) | SMN1; SMN2LMNAPOLBCA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105367-A | Buffered microcapsule compositions and methods | 第一牙科产品公司 | 2020-12-18 | — | — | CN | claimed |
| CN-102380100-A | Stable protease composition | TROBIO AB | 2012-03-21 | — | — | CN | claimed |
| EP-1637141-B1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | TROBIO AB (SE) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131234-A1 | SENSOR APPARATUS ADAPTED TO BE INCORPORATED IN A GARMENT | WEARABLE INFORMATION TECHNOLOGIES, S.L. (WEARTECH) (ES) | 2011-10-27 | — | — | WO | claimed |
| US-20090136474-A1 | Stabilized Protease Composition | TROBIO AB (SE) | 2009-05-28 | — | — | US | claimed |
| CN-101272790-A | Stable protease compositions | TROBIO AB (SE) | 2008-09-24 | — | — | CN | claimed |
| WO-2007035143-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2007-03-29 | — | — | WO | claimed |
| EP-1637141-A1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | Trobio AB (SE) | 2006-03-22 | — | — | EP | claimed |
| CN-112105367-A | Buffered microcapsule compositions and methods | 第一牙科产品公司 | 2020-12-18 | — | — | CN | disclosed |
| US-8574569-B2 | Stabilized protease composition | TROBIO AB (SE) | 2013-11-05 | — | — | US | disclosed |
| CN-101677947-B | Pharmaceutical formulation comprising an insulin derivative | NOVO NORDISK AS | 2013-07-17 | — | — | CN | disclosed |
| US-20130157339-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2013-06-20 | — | — | US | disclosed |
| US-8394372-B2 | Stabilized protease composition | TROBIO AB (SE) | 2013-03-12 | — | — | US | disclosed |
| CN-102666584-A | Blocking anti-DKK-1 antibodies and their uses | PFIZER | 2012-09-12 | — | — | CN | disclosed |
| CN-101705186-A | Defined cell culture surfaces and methods of use thereof | BECTON DICKINSON CO | 2010-05-12 | — | — | CN | disclosed |
| CN-101677947-A | pharmaceutical formulation comprising an insulin derivative | NOVO NORDISK AS | 2010-03-24 | — | — | CN | disclosed |
| US-20090136474-A1 | Stabilized Protease Composition | TROBIO AB (SE) | 2009-05-28 | — | — | US | disclosed |
| CN-101272790-A | Stable protease compositions | TROBIO AB (SE) | 2008-09-24 | — | — | CN | disclosed |
| WO-2007035143-A1 | STABILIZED PROTEASE COMPOSITION | TROBIO AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| EP-1637141-A1 | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease | Trobio AB (SE) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136474-A1 | Stabilized Protease Composition | SERPINE1, SERPINB1, CTRL | SMN1; SMN2 655/4885LMNA 505/4885POLB 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.